The Epidemiology Research Core (ERC) supports population-based research by providing access to metropolitan Detroit cancer cases and the cancer registry data for research. The Core also provides epidemiology consulting and collaborates with KCI members conducfing investigations in cancer prevention, etiology, treatment and outcomes. This mission is achieved through services including rapid case ascertainment (RCA) for population-based case enrollment;collection of medical records and biospecimens for population-tjased cases;abstracting medical records for study-specific information for population-based cases;linkage of datasets to patient data for diagnostic, treatment, and outcomes data;identifying population-based control groups;oversight and support of population-based study participant recruitment and interviewing;and epidemiologic expertise and collaboration for the conduct of population-based investigations of cancer. These objectives are achievable because WSU and KCI house the Metropolitan Detroit Cancer Surveillance System (MDCSS), an NCI-funded population-based Surveillance Epidemiology and End Results (SEER) registry covering the metropolitan Detroit population of four million residents. This population represents a large number of minorities, with -25% of the 25,000 annual cancer diagnoses in the SEER catchment area being African American, making the population ideal for the study of health disparities. The ERC benefits KCI by centralizing access to SEER data and standardizing patient, physician and hospital interactions for research relying on identification of and access to study participants for populafion-based research.
The ERC provides the necessary support to KCI members and other investigators for access to and utilizafion of cancer registry data and pafients for entry into population-based investigations of cancer prevention, etiology, treatment and outcomes. This type of population-based cancer research is made possible by providing investigator access to the MDCSS and nafional SEER population data through the ERC.
|Neslund-Dudas, Christine M; McBride, Russell B; Kandegedara, Ashoka et al. (2018) Association between cadmium and androgen receptor protein expression differs in prostate tumors of African American and European American men. J Trace Elem Med Biol 48:233-238|
|Kraniak, Janice M; Chalasani, Anita; Wallace, Margaret R et al. (2018) Development of 3D culture models of plexiform neurofibroma and initial application for phenotypic characterization and drug screening. Exp Neurol 299:289-298|
|An, Myunggi; Yu, Chunsong; Xi, Jingchao et al. (2018) Induction of necrotic cell death and activation of STING in the tumor microenvironment via cationic silica nanoparticles leading to enhanced antitumor immunity. Nanoscale 10:9311-9319|
|Tamura, Koji; Yu, Jun; Hata, Tatsuo et al. (2018) Mutations in the pancreatic secretory enzymes CPA1 and CPB1 are associated with pancreatic cancer. Proc Natl Acad Sci U S A 115:4767-4772|
|Wu, Jheng-Yu; Xiang, Shengyan; Zhang, Mu et al. (2018) Histone deacetylase 6 (HDAC6) deacetylates extracellular signal-regulated kinase 1 (ERK1) and thereby stimulates ERK1 activity. J Biol Chem 293:1976-1993|
|Negmeldin, Ahmed T; Knoff, Joseph R; Pflum, Mary Kay H (2018) The structural requirements of histone deacetylase inhibitors: C4-modified SAHA analogs display dual HDAC6/HDAC8 selectivity. Eur J Med Chem 143:1790-1806|
|Bao, Xun; Wu, Jianmei; Sanai, Nader et al. (2018) A liquid chromatography with tandem mass spectrometry method for quantitating total and unbound ceritinib in patient plasma and brain tumor. J Pharm Anal 8:20-26|
|Matherly, Larry H; Hou, Zhanjun; Gangjee, Aleem (2018) The promise and challenges of exploiting the proton-coupled folate transporter for selective therapeutic targeting of cancer. Cancer Chemother Pharmacol 81:1-15|
|Pollack, Murray M; Holubkov, Richard; Reeder, Ron et al. (2018) PICU Length of Stay: Factors Associated With Bed Utilization and Development of a Benchmarking Model. Pediatr Crit Care Med 19:196-203|
|Ali, Arif N; Zhang, Peixin; Yung, W K Alfred et al. (2018) NRG oncology RTOG 9006: a phase III randomized trial of hyperfractionated radiotherapy (RT) and BCNU versus standard RT and BCNU for malignant glioma patients. J Neurooncol 137:39-47|
Showing the most recent 10 out of 826 publications